

**Diaceutics PLC**  
**("Diaceutics" or the "Company")**

**Commercial launch of DXRX - The Diagnostic Network®**  
*Proprietary diagnostic network platform solution for precision medicine*

- *Diaceutics launches their proprietary diagnostic network for precision medicine, [DXRX - The Diagnostic Network®](#) to solve the significant issues facing testing ecosystem*
- *The platform provides access to a pipeline of global diagnostic testing data on one secure platform and enables industry-wide collaboration which is expected to accelerate biomarker test adoption and time to peak therapy prescription from years to just months*
- *Early collaborations are now live on DXRX with pharma, labs and diagnostic companies benefitting from the technology in EU, US and Asian markets*

Diaceutics PLC, (AIM: DXRX), announces the launch of DXRX - The Diagnostic Network® ("DXRX") digital platform. The platform has been designed to accelerate the development and commercialisation of precision medicine diagnostics using a new operating model. DXRX integrates a pipeline of global diagnostic testing data into one secure platform and brings together stakeholders from across the industry to collaborate in a vibrant forum in a secure, standardised way.

Early collaborations between pharma, labs and diagnostic companies are now live on DXRX's platform which enables cross-industry collaboration on testing hurdles at any stage of the development and commercialisation process.

One such recent collaboration to go live this week focusses on addressing PD-L1 test reimbursement in the US. Users are invited to share real world data to enable the creation of an improved reimbursement model. PD-L1 is an immune-related biomarker that is expressed on tumour cells in various tumour types, including non-small-cell lung carcinoma ("NSCLC"). The desired outcome of this collaboration is to establish a more realistic level of reimbursement for PD-L1 testing through the assignment of a reimbursement coding specific to the biomarker, as evidenced in the 2020 Pharma Readiness ("PM") report published recently by the Company. Data given in the report reveals that, although PD-L1 has a test adoption rate of 80% for NSCLC, hurdles such as reimbursement, which are inadequately addressed at the planning stage, have resulted in a time to test adoption of up to four years with only 50% of patients getting the right treatment at the right time. This is an industry red flag needing urgent addressing for patients.

**Chief Executive Officer at Diaceutics, Peter Keeling said:** *"We believe that DXRX sets a new industry standard for precision medicine which, until today, has been reliant upon an operational model entirely unfit for purpose. It places laboratories at the centre of a precision medicine network, enables diagnostic companies to extract more value from the industry, and allows pharma to deliver seamless diagnostic testing for their precision medicines through collaboration on one, secure platform."*

To read the full marketing launch press release, please see here: <https://www.diaceutics.com/articles/diaceutics-launches-worlds-first-diagnostic-network-for-precision-medicine-to-solve-global-cancer-testing-issues>

Enquiries:

**Diaceutics PLC**

Philip White, Chief Financial Officer

*Via Walbrook PR*

**Cenkos Securities plc (Nomad & Broker)**

Tel: +44 (0)20 7397 8900

Callum Davidson / Giles Balleny  
Michael Johnson (Sales)

**Walbrook PR**

Tel: +44 (0)20 7933 8780 or [diaceutics@walbrookpr.com](mailto:diaceutics@walbrookpr.com)

Anna Dunphy  
Paul McManus

Tel: +44 (0)7876 741 001  
Tel: +44 (0)7980 541 893

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - a proprietary diagnostic network solution for the development and commercialisation of precision medicine diagnostics. Diaceutics has created commercially useful data sets for every precision medicine brought to market and provides services to 36 of the world's leading pharmaceutical companies. We have built the world's largest repository of diagnostic testing data with a growing network of 2,500 labs in 51 countries.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

PRLMRBRTMTBTBJM